Elizabeth Selvin1, Alan T Hirsch. 1. Department of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21287, USA. lselvin@jhsph.edu
Abstract
BACKGROUND: Lower extremity peripheral arterial disease (PAD) is a coronary heart disease (CHD) risk equivalent. Selected studies have demonstrated less intense risk factor management and diminished mobility in individuals with PAD as compared to individuals with clinical recognized CHD. However, comparable data have not been reported from a nationally representative population. OBJECTIVES: To assess the prevalence, treatment, and control of cardiovascular risk factors among individuals with PAD as defined by an ankle-brachial index (ABI) <0.90 (but without recognized CHD) as compared with individuals with recognized CHD (but without PAD). A second objective was to evaluate the diagnostic accuracy of measures of walking dysfunction to identify individuals with PAD. DESIGN, SETTING, AND PARTICIPANTS: We analyzed data from 7571 participants aged 40 or older who participated in the National Health and Nutrition Examination Survey (NHANES) 1999-2004, a nationally representative cross-sectional survey of the U.S. population. RESULTS: The prevalence of PAD without CHD was 4.1% (95% CI 3.6-4.5) compared to 7.9% (7.1, 8.9) for CHD (without PAD). Hypertension prevalence was similar, but treatment and control rates were lower among individuals with PAD compared to CHD (treatment: 69% vs. 84%, p<0.001; control: 50% vs. 63%, p=0.01). Treatment of hypercholesterolemia was lower among individuals with PAD (54% vs. 79%, p<0.001) but control was similar (83% vs. 85%, p=0.78). Diabetes awareness, treatment, and control did not differ between the two groups. Walking mobility limitations were specific, but insensitive, for the identification of individuals with PAD. CONCLUSION: PAD in the absence of clinically recognized CHD is under-treated and poorly controlled in the general U.S. population. Leg symptoms are not adequate to identify individuals with PAD, who are at high risk of ischemic events.
BACKGROUND: Lower extremity peripheral arterial disease (PAD) is a coronary heart disease (CHD) risk equivalent. Selected studies have demonstrated less intense risk factor management and diminished mobility in individuals with PAD as compared to individuals with clinical recognized CHD. However, comparable data have not been reported from a nationally representative population. OBJECTIVES: To assess the prevalence, treatment, and control of cardiovascular risk factors among individuals with PAD as defined by an ankle-brachial index (ABI) <0.90 (but without recognized CHD) as compared with individuals with recognized CHD (but without PAD). A second objective was to evaluate the diagnostic accuracy of measures of walking dysfunction to identify individuals with PAD. DESIGN, SETTING, AND PARTICIPANTS: We analyzed data from 7571 participants aged 40 or older who participated in the National Health and Nutrition Examination Survey (NHANES) 1999-2004, a nationally representative cross-sectional survey of the U.S. population. RESULTS: The prevalence of PAD without CHD was 4.1% (95% CI 3.6-4.5) compared to 7.9% (7.1, 8.9) for CHD (without PAD). Hypertension prevalence was similar, but treatment and control rates were lower among individuals with PAD compared to CHD (treatment: 69% vs. 84%, p<0.001; control: 50% vs. 63%, p=0.01). Treatment of hypercholesterolemia was lower among individuals with PAD (54% vs. 79%, p<0.001) but control was similar (83% vs. 85%, p=0.78). Diabetes awareness, treatment, and control did not differ between the two groups. Walking mobility limitations were specific, but insensitive, for the identification of individuals with PAD. CONCLUSION: PAD in the absence of clinically recognized CHD is under-treated and poorly controlled in the general U.S. population. Leg symptoms are not adequate to identify individuals with PAD, who are at high risk of ischemic events.
Authors: A B Newman; L Shemanski; T A Manolio; M Cushman; M Mittelmark; J F Polak; N R Powe; D Siscovick Journal: Arterioscler Thromb Vasc Biol Date: 1999-03 Impact factor: 8.311
Authors: Z J Zheng; A R Sharrett; L E Chambless; W D Rosamond; F J Nieto; D S Sheps; A Dobs; G W Evans; G Heiss Journal: Atherosclerosis Date: 1997-05 Impact factor: 5.162
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: Edward W Gregg; Paul Sorlie; Ryne Paulose-Ram; Qiuping Gu; Mark S Eberhardt; Michael Wolz; Vicki Burt; Lester Curtin; Michael Engelgau; Linda Geiss Journal: Diabetes Care Date: 2004-07 Impact factor: 19.112
Authors: Alan T Hirsch; Peter Gloviczki; Alain Drooz; Marge Lovell; Mark A Creager Journal: Vasc Endovascular Surg Date: 2004 Mar-Apr Impact factor: 1.089
Authors: Marie D Gerhard-Herman; Heather L Gornik; Coletta Barrett; Neal R Barshes; Matthew A Corriere; Douglas E Drachman; Lee A Fleisher; Francis Gerry R Fowkes; Naomi M Hamburg; Scott Kinlay; Robert Lookstein; Sanjay Misra; Leila Mureebe; Jeffrey W Olin; Rajan A G Patel; Judith G Regensteiner; Andres Schanzer; Mehdi H Shishehbor; Kerry J Stewart; Diane Treat-Jacobson; M Eileen Walsh Journal: Circulation Date: 2016-11-13 Impact factor: 29.690
Authors: Mary M McDermott; George Reed; Philip Greenland; Kathy M Mazor; Sherry Pagoto; Judith K Ockene; Rex Graff; Philip A Merriam; Kathy Leung; Larry Manheim; Melina R Kibbe; Barbara Olendzki; William H Pearce; Ira S Ockene Journal: Am J Med Date: 2011-06 Impact factor: 4.965
Authors: Yasuyuki Honda; Yejin Mok; Lena Mathews; Jeremy R Van't Hof; Gail Daumit; Anna Kucharska-Newton; Elizabeth Selvin; Thomas Mosley; Josef Coresh; Kunihiro Matsushita Journal: Atherosclerosis Date: 2021-05-09 Impact factor: 6.847